Latest Financial Position News

BDO Audit has completed its review of HeraMED Limited’s half-year financial report for June 2025, confirming compliance with accounting standards but highlighting significant uncertainty over the company’s ability to continue as a going concern.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

Experience Co Limited reported a 6% increase in revenue to $134.3 million for FY25, alongside a 34% rise in underlying EBITDA to $19.3 million, marking its best financial performance since FY19. The company declared a fully franked dividend and initiated a 10% on-market share buy-back.

Steadfast Group has reported a robust 17.2% increase in underlying net profit after tax for FY25, alongside a 14% rise in its fully franked final dividend, underpinned by both organic growth and strategic acquisitions.

ARC Funds Limited posted a $2.45 million loss for FY2025, driven by strategic investments and increased transaction costs as it expands its funds management platform.

NTAW Holdings reported a slight revenue increase to $538 million for FY2025 but posted a significant net loss of $44 million, driven by a $39 million impairment charge and operational challenges including the loss of Dunlop distribution rights. The company is executing a business reset focusing on inventory, costs, and cash flow.

FortifAI Limited reported a 15% decline in game revenue to $4.3 million for FY2025 but achieved a significant 72% reduction in net loss to $1.99 million, supported by operational cost cuts and a $3.6 million capital raise.

BTC Health reports a strong FY25 with a $4 million statutory profit, boosted by a $5 million contract and strategic acquisition. The company eyes further growth in FY26 with new product launches and expanded market reach.

CI1 reported a sharp 57% revenue decline in FY25 but reduced its comprehensive loss by 64% through strategic disposals and capital returns. The company’s financial services operations in Australia and Singapore faced tough market conditions, prompting a portfolio reshaping.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit for FY25, marking the completion of its transformative Simply Stronger program that enhanced digital offerings and customer reach.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.